A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)

This study has been terminated.
(Terminated early dt to acquisition of Sponsor and change in corporate priorities)
Sponsor:
Information provided by (Responsible Party):
Aires Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01725256
First received: November 8, 2012
Last updated: April 7, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: February 2014
  Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)